Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.42 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20340745 | 0.93 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5FURIN | |
| SCHEMBL19084461 | 0.93 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5FURIN | |
| SCHEMBL18660691 | 0.90 | SIRT2 (0.40) | SIRT2SIRT1SIRT3SIRT5FURIN | |
| SCHEMBL24450761 | 0.90 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5FURIN | |
| SCHEMBL22546818 | 0.90 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5FURIN | |
| SCHEMBL20798918 | 0.90 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5FURIN | |
| SCHEMBL24451192 | 0.90 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5FURIN | |
| SCHEMBL21566760 | 0.87 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5FURIN | |
| SCHEMBL22541220 | 0.86 | FURIN (0.40) | SIRT2SIRT1SIRT3SIRT5FURIN | |
| SCHEMBL20435038 | 0.85 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239957-B2 | Peptide containing conjugates for dual molecular delivery of oligonucleotides | MERCK SHARP & DOHME CORP. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190015442-A1 | DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES AND PEPTIDE CONTAINING CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10010562-B2 | Dual molecular delivery of oligonucleotides and peptide containing conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170189441-A1 | DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES AND PEPTIDE CONTAINING CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170081425-A1 | PEPTIDE CONTAINING CONJUGATES FOR DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010562-B2 | Dual molecular delivery of oligonucleotides and peptide containing conjugates | DCLRE1A, DCLRE1B, LNPEP | SIRT2 3590/4885SIRT1 3858/4885SIRT3 4003/4885 |
| US-20190015442-A1 | DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES AND PEPTIDE CONTAINING CONJUGATES | DCLRE1A, DCLRE1B, LNPEP | SIRT2 3828/4885SIRT1 4066/4885SIRT3 4120/4885 |
| US-10239957-B2 | Peptide containing conjugates for dual molecular delivery of oligonucleotides | AGBL2, LNPEP, DCLRE1B | SIRT2 4328/4885SIRT1 4653/4885SIRT3 4701/4885 |
| US-20170081425-A1 | PEPTIDE CONTAINING CONJUGATES FOR DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES | AGBL2, LNPEP, DCLRE1B | SIRT2 4328/4885SIRT1 4653/4885SIRT3 4701/4885 |
| US-20170189441-A1 | DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES AND PEPTIDE CONTAINING CONJUGATES | DCLRE1A, DCLRE1B, LNPEP | SIRT2 3590/4885SIRT1 3858/4885SIRT3 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.